Clinical trial
Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma
NCT00216424 · James A. Haley Veterans Administration Hospital, U.S. Fed · Terminated
Key facts
| NCT number | NCT00216424 |
|---|---|
| Title | Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma |
| Official title | An Open Label, Phase II Study of Capecitabine (Xeloda) Plus Conformal Radiotherapy for Patients With Locally Advanced, Non-Metastatic Rectosigmoid Carcinoma |
| Lead sponsor | James A. Haley Veterans Administration Hospital, U.S. Fed |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine (Xeloda) |
| Enrollment | 40 |
| Start date | Feb 1, 2005 |
| Completion | Jan 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 12, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: